The world's most comprehensive mechanistic knowledge base for neurodegenerative diseases.
NeuroWiki maps the causal chains from genes to proteins to pathways to disease, creating a densely connected, evidence-backed knowledge graph spanning Alzheimer's, Parkinson's, CBS, PSP, ALS, FTD, and Huntington's disease. Currently 16,000+ published pages with continuous AI-driven expansion.
Knowledge Base at a Glance
flowchart TD
home["NeuroWiki"]
style home fill:#4fc3f7,stroke:#333,color:#000
home_0["Knowledge Base at a Glance"]
home -->|"includes"| home_0
style home_0 fill:#81c784,stroke:#333,color:#000
home_1["Disease Focus Areas"]
home -->|"includes"| home_1
style home_1 fill:#ef5350,stroke:#333,color:#000
home_2["Alzheimers Disease AD"]
home -->|"includes"| home_2
style home_2 fill:#ffd54f,stroke:#333,color:#000
home_3["Parkinsons Disease PD"]
home -->|"includes"| home_3
style home_3 fill:#ce93d8,stroke:#333,color:#000
home_4["Corticobasal Syndrome CBS / Corticobasal Degen"]
home -->|"includes"| home_4
style home_4 fill:#4fc3f7,stroke:#333,color:#000
home_5["Progressive Supranuclear Palsy PSP"]
home -->|"includes"| home_5
style home_5 fill:#81c784,stroke:#333,color:#000
...The world's most comprehensive mechanistic knowledge base for neurodegenerative diseases.
NeuroWiki maps the causal chains from genes to proteins to pathways to disease, creating a densely connected, evidence-backed knowledge graph spanning Alzheimer's, Parkinson's, CBS, PSP, ALS, FTD, and Huntington's disease. Currently 16,000+ published pages with continuous AI-driven expansion.
Knowledge Base at a Glance
Mermaid diagram (expand to render)
| Section | Pages | Description |
|---------|------:|-------------|
| [Genes](/genes) | 3,850 | Disease-associated genes, risk variants, GWAS findings, expression patterns |
| [Cell Types](/cell-types) | 3,573 | Neuronal subtypes, glia, immune cells — morphology, markers, disease roles |
| [Proteins](/proteins) | 3,189 | Protein structure, function, aggregation, post-translational modifications |
| [Mechanisms](/mechanisms) | 1,803 | Molecular pathways from protein misfolding to neuronal death |
| [Therapeutics](/therapeutics) | 1,066 | Drug therapies, biologics, gene therapy, clinical interventions |
| [Companies](/companies) | 638 | Pharma, biotech, diagnostics — pipelines, programs, partnerships |
| [Diseases](/diseases) | 514 | Disease pages, subtypes, clinical features, diagnostic criteria |
| [Clinical Trials](/clinical-trials) | 493 | Active and completed trials across all disease areas |
| [Institutions](/institutions) | 311 | Research universities, hospitals, consortia, foundations |
| [Ideas](/ideas) | 233 | Novel therapeutic hypotheses, ranked by evidence strength |
| [Researchers](/researchers) | 216 | Key investigators, their contributions and publications |
| [Experiments](/experiments) | 187 | Proposed experiments with protocols, costs, and rankings |
| [Entities](/entities) | 185 | Cross-cutting molecular entities and complexes |
| [Biomarkers](/biomarkers) | 185 | CSF, blood, PET, digital, and emerging diagnostic markers |
| [Technologies](/technologies) | 160 | Therapeutic platforms — ASOs, gene therapy, antibodies, PROTACs |
| [Events](/events) | 124 | Conferences, workshops — AD/PD, AAIC, CTAD, SfN |
| [Investment](/investment) | 99 | Funding landscape, venture activity, market analysis |
| [Diagnostics](/diagnostics) | 95 | Diagnostic tools, accuracy comparisons, clinical utility |
| [Hypotheses](/hypotheses) | 79 | Testable disease hypotheses with evidence scoring |
| [Gaps](/gaps) | 55 | Knowledge gaps, research opportunities, unmet needs |
| [Brain Regions](/brain-regions) | 54 | Neuroanatomy, vulnerability patterns, circuit dysfunction |
| [Circuits](/circuits) | 39 | Neural circuit models and connectivity |
| [Datasets](/datasets) | 26 | Public datasets for neurodegeneration research |
| [Organizations](/organizations) | 35 | Patient organizations, foundations, societies |
| [Projects](/projects) | 22 | Research initiatives, consortia, funding programs |
| [Models](/models) | 15 | Animal models, cell models, experimental systems |
| [Resources](/resources) | 1 | Research resources, biobanks, data repositories |
Total: 17,299 pages across 27 sections
Disease Focus Areas
Alzheimer's Disease (AD)
The most common neurodegenerative disease. NeuroWiki covers the full mechanistic landscape: [amyloid-beta](/proteins/amyloid-beta) plaque formation, [tau](/proteins/tau) neurofibrillary tangles, neuroinflammation, synaptic dysfunction, vascular contributions, and emerging hypotheses (metabolic, infectious, autoimmune). Includes comprehensive coverage of therapeutic antibodies ([lecanemab](/therapeutics/lecanemab), [donanemab](/therapeutics/donanemab)), biomarkers (p-tau217, amyloid PET), and 200+ clinical trials.
Parkinson's Disease (PD)
Coverage spans [alpha-synuclein](/proteins/alpha-synuclein) aggregation, LRRK2 signaling, GBA/lysosomal dysfunction, mitochondrial Complex I deficiency, gut-brain axis, and dopaminergic neuron vulnerability. Therapeutic coverage includes GLP-1 agonists, LRRK2 inhibitors, gene therapy, and cell replacement approaches.
Corticobasal Syndrome (CBS) / Corticobasal Degeneration (CBD)
Deep coverage of 4R-tau pathology, astrocytic plaques, diagnostic challenges (Armstrong criteria), and the limited but growing therapeutic pipeline. NeuroWiki aims to be the most comprehensive CBS resource available.
Progressive Supranuclear Palsy (PSP)
Comprehensive coverage of tufted astrocytes, globose neurofibrillary tangles, midbrain atrophy, PSP subtypes (Richardson syndrome, PSP-P, PSP-CBS), and the full clinical trial landscape. Connected to the broader 4R-tauopathy research community.
ALS, FTD, and Huntington's Disease
Expanding coverage of TDP-43 proteinopathy, C9orf72 repeat expansions, SOD1 mutations, FUS pathology, and the ALS-FTD spectrum. Huntington's coverage includes HTT gene biology and emerging therapeutic approaches.
How NeuroWiki Works
Mechanistic Knowledge Graph
Every page is densely cross-linked. A gene page links to its protein product, which links to pathways it participates in, which link to diseases they contribute to, which link to therapeutics targeting them. This creates a navigable web of mechanistic understanding.
Evidence-Based Content
All content is backed by peer-reviewed literature with PubMed-linked references and DOI-linked citations.
AI-Driven Continuous Expansion
NeuroWiki is continuously expanded by AI agents running 24/7, systematically:
- Crawling Alzforum, PubMed, and conference proceedings for new findings
- Generating and ranking therapeutic hypotheses
- Designing experimental proposals with detailed protocols and cost estimates
- Tracking clinical trials across all disease areas
- Identifying and filling knowledge gaps
Rankings and Quality Scoring
Key sections include ranked indexes:
- [Therapeutic Rankings](/therapeutics/rankings) — efficacy and evidence scoring
- [Company Rankings](/companies/rankings) — pipeline and clinical progress
- [Idea Rankings](/ideas/rankings) — therapeutic hypothesis scoring (10 dimensions)
- [Research Gap Overview](/gaps/overview) — prioritized knowledge gaps
Quick Navigation
By Disease: [Alzheimer's](/diseases/alzheimers-disease) | [Parkinson's](/diseases/parkinsons-disease) | [ALS](/diseases/amyotrophic-lateral-sclerosis) | [FTD](/diseases/frontotemporal-dementia) | [Huntington's](/diseases/huntingtons) | [CBS](/diseases/corticobasal-degeneration) | [PSP](/diseases/progressive-supranuclear-palsy)
By Section: [All Pages](/all-pages) | [Genes](/genes) | [Proteins](/proteins) | [Mechanisms](/mechanisms) | [Therapeutics](/therapeutics) | [Clinical Trials](/clinical-trials) | [Biomarkers](/biomarkers) | [Companies](/companies) | [Technologies](/technologies)
Special: [Therapeutic Ideas](/ideas/overview) | [Experiment Proposals](/experiments) | [Events & Conferences](/events) | [Research Gaps](/gaps/overview) | [Hypotheses](/hypotheses/overview)
Meta: [Tags & Taxonomy](/Meta/tags) | [Organizations](/organizations)
References
Unknown, NeuroWiki project. Mechanistic wiki for neurodegenerative diseases. 2024-2026 (2024)
Unknown, Page count as of March 2026. Continuously updated by AI agents (2026)
Unknown, Knowledge graph approach inspired by Gene Ontology and Disease Ontology frameworks (n.d.)
Unknown, Cross-linking methodology based on biomedical entity recognition and relationship extraction (n.d.)
Unknown, All references verified against PubMed (pubmed.ncbi.nlm.nih.gov) and DOI resolution (n.d.)
Unknown, Continuous expansion powered by Orchestra multi-agent orchestration system (n.d.)From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
- [Purinergic P2Y12 Inverse Agonist Therapy](/hypothesis/h-f99ce4ca) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: P2RY12
- [Extracellular Matrix Stiffness Modulation](/hypothesis/h-725c62e9) — <span style="color:#ffd54f;font-weight:600">0.53</span> · Target: PIEZO1
- [Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: SIRT1
- [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
- [Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SST
- [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
- [Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: ABCA1/LDLR/SREBF2
- [Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: NLRP3, CASP1, IL1B, PYCARD
Related Analyses:
- [Immune atlas neuroinflammation analysis in neurodegeneration](/analysis/SDA-2026-04-02-gap-immune-atlas-neuroinflam-20260402) 🔄
- [Microglial subtypes in neurodegeneration — friend vs foe](/analysis/SDA-2026-04-02-gap-microglial-subtypes-20260402004119) 🔄
- [Neuroinflammation resolution mechanisms and pro-resolving mediators](/analysis/SDA-2026-04-01-gap-014) 🔄
- [Mitochondrial transfer between astrocytes and neurons](/analysis/SDA-2026-04-01-gap-v2-89432b95) 🔄
- [Perivascular spaces and glymphatic clearance failure in AD](/analysis/SDA-2026-04-01-gap-v2-ee5a5023) 🔄